U.S. spending on GLP-1 receptor agonists reached $71.7 billion in 2023. Semaglutide and tirzepatide products have captured 70% of the market as diabetes and weight loss medication use rapidly expands, according to new research.
March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
Researchers highlight evidence-based lifestyle and pharmacologic strategies, including glycemic excursion minimization and tirzepatide, for early glycemic control in adults with type 2 diabetes.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
Colorectal cancer patients face up to 45% higher cardiovascular mortality risk within two years of diagnosis, with Black patients and those under 50 experiencing the greatest danger, according to research presented at ACC.25.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
"Partial weight regain after substantial weight loss was associated with a less favorable cardiovascular risk profile and an increased incidence of both microvascular and macrovascular diseases."
The FDA has approved guselkumab (TREMFYA®) for moderately to severely active Crohn’s disease, supported by Phase 3 trial data showing clinical and endoscopic superiority over ustekinumab.
Chomps beef and turkey sticks pulled from shelves in multi-state recall after metal fragments discovered; manufacturer urges consumers to check lot codes and return affected products for refund.